Definitely. Thank you for raising the question.
With rare diseases, it is something that would be wonderful to include within pharmacare. I think that is everyone's vision going forward, recognizing, of course, that we might need to have a bit of a separate strategy in terms of how to identify the most efficacious medications and how to also purchase the medications themselves, given that oftentimes because they're for a smaller population they can be extremely costly and expensive. That being said, a lot of these very expensive medications can make a tremendous impact on somebody's life and ability to function and have a quality of life and also contribute to society and participate.
Absolutely, I really was thrilled to see that. The Hoskins report specifically mentioned that the area of rare diseases needs its individual, separate strategy, and I was also really happy to see the funding toward it. I don't know if I or Canadian Doctors for Medicare have any ideal solutions, other than saying that we do absolutely need to look at these medications and to fund them. But we might need a bit of a different process given the very long-term ability to see that medications are safe. Sometimes we don't always have that luxury with rare diseases. So I'm glad to see that it's treated separately.